EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential

Zahra Nazari Taloki iD

BioImpacts · 25.05.2026 · 16 · 33590

DOI: 10.34172/bi.33590 ↗

Kurz gefasst

Leserbrief in der Zeitschrift BioImpacts, online erschienen am 25.05.2026. Verfasst von Zahra Nazari Taloki. Beteiligte Einrichtung: Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To Editor, Burn injuries frequently result in progressive tissue ischemia driven by microvascular dysfunction, oxidative stress, and inflammatory cascades, which impair tissue viability and delay healing.The zone of stasis-initially viable but vulnerable tissue surrounding the necrotic core-represents a key therapeutic target, as its progression to irreversible necrosis markedly worsens outcomes.1,2 Despite advances in burn care, pharmacologic agents specifically designed to preserve microvascular perfusion and cellular integrity in this region remain limited.Levosimendan, a calcium sensitizer and ATP-sensitive potassium (KATP) channel opener with an established role in acute heart failure, exerts cytoprotective effects beyond its inotropic actions.3 These include vasodilation, mitochondrial stabilization, reduction of oxidative stress markers (e.g., malondialdehyde, nitric oxide), restoration of antioxidant enzyme activity (e.g., superoxide dismutase), and modulation of inflammatory pathways (e.g., improved IL-10/IL-6 ratio, reduced TNF-α and IL-6).[3][4][5][6][7] Experimental studies have shown levosimendan mitigates ischemia-reperfusion (I/R) injury in heart, lung, kidney, intestine, and brain, improving tissue oxygenation, endothelial function, and cellular resilience under ischemic conditions.[5][6][7][8][9][10] These mechanisms align with the core drivers of burn zone-of-stasis progression: reactive oxygen species accumulation, endothelial dysfunction, proinflammatory cytokine release, and impaired regional perfusion.1,2 In non-burn ischemic and inflammatory models, levosimendan has reduced oxidative damage, preserved tissue viability, and enhanced perfusion without increasing oxygen demand.[6][7][8][9][10][11][12][13] While these findings provide mechanistic plausibility, "However, no data exist

Autor:innen und Institutionen

  • Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Babol University of Medical Sciences, Babol, Iran.

ORCID-Profile: Zahra Nazari Taloki

Zitieren

APA

Nazari Taloki, Z. (2026). Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential. BioImpacts, 16, 33590. https://doi.org/10.34172/bi.33590

Vancouver

Nazari Taloki Z. Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential. BioImpacts. 2026;16:33590. doi:10.34172/bi.33590

BibTeX
@article{NazariTaloki2026,
  author = {Nazari Taloki, Zahra},
  title = {Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential},
  journal = {BioImpacts},
  year = {2026},
  volume = {16},
  pages = {33590},
  doi = {10.34172/bi.33590}
}
Kostenlos starten →